Leland Gershell
Stock Analyst at Oppenheimer
(4.32)
# 373
Out of 4,900 analysts
135
Total ratings
42.06%
Success rate
23.09%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $76 → $110 | $89.36 | +23.10% | 2 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Upgrades: Outperform | $60 | $46.97 | +27.75% | 2 | Jul 9, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $43 → $22 | $7.18 | +206.62% | 5 | Jun 23, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $215 → $224 | $174.75 | +28.18% | 12 | Jun 13, 2025 | |
| URGN UroGen Pharma | Maintains: Outperform | $10 → $31 | $14.04 | +120.80% | 11 | Jun 13, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $10 | $1.38 | +624.64% | 1 | Jun 6, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $7 | $5.28 | +32.58% | 2 | May 9, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $704 → $708 | $554.71 | +27.63% | 7 | May 9, 2025 | |
| QNCX Quince Therapeutics | Initiates: Outperform | $10 | $1.74 | +474.71% | 1 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $12 → $20 | $6.86 | +191.55% | 3 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $56.62 | +73.08% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $19.01 | +173.54% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.58 | +760.88% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.87 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $73 | $83.59 | -12.67% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $17.49 | +203.03% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $3.48 | +763.31% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $2.54 | +372.44% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $0.05 | +49,700.80% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $16.26 | +72.20% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $3.05 | +719.67% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $31.84 | +129.27% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $2.05 | +875.61% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $20.95 | +38.42% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $4.80 | +629.17% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.70 | +1,327.14% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.17 | +1,609.40% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $311.12 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.48 | +778.38% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $1.47 | +8,063.27% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.70 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $360,000 | $0.83 | +43,446,677.70% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $16.04 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.36 | +3,576.47% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $15.83 | - | 5 | Mar 31, 2020 |
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $89.36
Upside: +23.10%
BridgeBio Pharma
Jul 9, 2025
Upgrades: Outperform
Price Target: $60
Current: $46.97
Upside: +27.75%
Capricor Therapeutics
Jun 23, 2025
Maintains: Outperform
Price Target: $43 → $22
Current: $7.18
Upside: +206.62%
Ascendis Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $174.75
Upside: +28.18%
UroGen Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $14.04
Upside: +120.80%
Climb Bio
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $1.38
Upside: +624.64%
Xeris Biopharma Holdings
May 9, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $5.28
Upside: +32.58%
argenx SE
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $554.71
Upside: +27.63%
Quince Therapeutics
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.74
Upside: +474.71%
Trevi Therapeutics
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $6.86
Upside: +191.55%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $56.62
Upside: +73.08%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $19.01
Upside: +173.54%
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.58
Upside: +760.88%
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.87
Upside: -
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $83.59
Upside: -12.67%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $17.49
Upside: +203.03%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $3.48
Upside: +763.31%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.54
Upside: +372.44%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $0.05
Upside: +49,700.80%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $16.26
Upside: +72.20%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $3.05
Upside: +719.67%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $31.84
Upside: +129.27%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $2.05
Upside: +875.61%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $20.95
Upside: +38.42%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $4.80
Upside: +629.17%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.70
Upside: +1,327.14%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.17
Upside: +1,609.40%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $311.12
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.48
Upside: +778.38%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $1.47
Upside: +8,063.27%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.70
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $360,000
Current: $0.83
Upside: +43,446,677.70%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $16.04
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.36
Upside: +3,576.47%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $15.83
Upside: -